Jade Biosciences
JBIO
41 hedge funds and large institutions have $453M invested in Jade Biosciences in 2021 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.
480% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 5
141% more funds holding
Funds holding: 17 → 41 (+24)
2.53% more ownership
Funds ownership: 0% → 2.53% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less capital invested
Capital invested by funds: $454M → $453M (-$1.85M)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.5M |
| 2 |
BlackRock
New York
|
+$7.73M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$3.58M |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$2.27M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.84M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.54M |
| 3 |
Goldman Sachs
New York
|
-$2.39M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$481K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$323K |
JBIO Hedge Fund Activity: Q3 2021 in Review
41 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q3 2021, worth a combined $453M — down 0.41% from $454M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new JBIO positions and 5 closed out — a net gain of 24 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $12.5M. The largest seller was Fidelity Investments, cutting an estimated $2.84M.
- 41 institutional investors held Jade Biosciences (JBIO) as of Q3 2021, up from 17 in Q2 2021.
- Funds reported $453M of Jade Biosciences stock for Q3 2021, down 0.41% quarter-over-quarter.
- 29 funds opened new Jade Biosciences positions in Q3 2021 and 5 closed out, a net change of +24 holders.
- The largest Jade Biosciences buyer in Q3 2021 was Vanguard Group, an estimated $12.5M added.
- The largest Jade Biosciences seller in Q3 2021 was Fidelity Investments, an estimated $2.84M sold.
Based on aggregated 13F filings for Q3 2021.